Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 394
- 试验地点
- 1
- 主要终点
- Endocrine remission rate
研究概览
简要总结
the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.
详细描述
Non-invasive prolactinomas were treated by transsphenoidal surgery or Dopamine agonist until now. However，this two type therapies were controversial. The study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •non-invasive prolactionma
排除标准
- •invasive prolactioma
研究组 & 干预措施
transsphenoidal surgery treatment
Transsphenoidal surgery treat non-invasive prolactinoma by experienced neurosurgeon
干预措施: transsphenoidal surgery treatment (Procedure)
dopamine agonist treatment
Minimum effective dose of dopamine agonist, bromocriptine, treat non-invasive prolactinoma
干预措施: dopamine agonist treatment (Drug)
结局指标
主要结局
Endocrine remission rate
时间窗: five-year
After intervention, blood prolactin normalization rate
次要结局
未报告次要终点
研究者
Hai-Jun Wang
director
First Affiliated Hospital, Sun Yat-Sen University